Dolores Isla , María D. Lozano , Luis Paz-Ares , Clara Salas , Javier de Castro , Esther Conde , Enriqueta Felip , Javier Gómez-Román , Pilar Garrido , Ana Belén Enguita
{"title":"确定非小细胞肺癌预测生物标志物的建议的新更新:西班牙病理解剖学会和西班牙医学肿瘤学会的全国共识","authors":"Dolores Isla , María D. Lozano , Luis Paz-Ares , Clara Salas , Javier de Castro , Esther Conde , Enriqueta Felip , Javier Gómez-Román , Pilar Garrido , Ana Belén Enguita","doi":"10.1016/j.patol.2023.02.002","DOIUrl":null,"url":null,"abstract":"<div><p>Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting <em>EGFR</em>, <em>BRAF</em>, <em>KRAS</em> and <em>MET</em> mutations, <em>ALK</em>, <em>ROS1</em>, <em>NTRK</em> and <em>RET</em> translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing (NGS) facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the <em>HER2</em> mutation and predictive biomarkers for immunotherapy responses.</p><p>In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.</p></div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica\",\"authors\":\"Dolores Isla , María D. Lozano , Luis Paz-Ares , Clara Salas , Javier de Castro , Esther Conde , Enriqueta Felip , Javier Gómez-Román , Pilar Garrido , Ana Belén Enguita\",\"doi\":\"10.1016/j.patol.2023.02.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting <em>EGFR</em>, <em>BRAF</em>, <em>KRAS</em> and <em>MET</em> mutations, <em>ALK</em>, <em>ROS1</em>, <em>NTRK</em> and <em>RET</em> translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing (NGS) facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the <em>HER2</em> mutation and predictive biomarkers for immunotherapy responses.</p><p>In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.</p></div>\",\"PeriodicalId\":39194,\"journal\":{\"name\":\"Revista Espanola de Patologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espanola de Patologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1699885523000077\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Patologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699885523000077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Nueva actualización de las recomendaciones para la determinación de biomarcadores predictivos en el carcinoma de pulmón no célula pequeña: Consenso Nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and MET mutations, ALK, ROS1, NTRK and RET translocations, and PD-L1 expression in these patients is considered essential. The use of next-generation sequencing (NGS) facilitates precise molecular diagnosis and allows the detection of other emerging mutations, such as the HER2 mutation and predictive biomarkers for immunotherapy responses.
In this consensus, a group of experts in the diagnosis and treatment of NSCLC selected by the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM) have evaluated currently available information and propose a series of recommendations to optimize the detection and use of biomarkers in daily clinical practice.